Blueprint Medicines Corporation (BPMC)
NASDAQ$89.58
Market Cap
$5.72B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
493 of 924
Rank in Industry
286 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BPMC Insider Trading Activity
BPMC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $39,679,204 | 46 | 100 |
Related Transactions
| McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 0 | $0 | 1 | $467,266 | $-467,266 |
| Namouni Fouad | PRESIDENT, R & D | 0 | $0 | 2 | $900,723 | $-900,723 |
| Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 3 | $993,247 | $-993,247 |
| Rossi Christina | CHIEF OPERATING OFFICER | 0 | $0 | 5 | $1.48M | $-1.48M |
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 0 | $0 | 3 | $1.82M | $-1.82M |
| COATS LONNEL | director | 0 | $0 | 2 | $1.87M | $-1.87M |
| Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 0 | $0 | 7 | $2.03M | $-2.03M |
| Landsittel Michael | CHIEF FINANCIAL OFFICER | 0 | $0 | 6 | $4.03M | $-4.03M |
| Lee Philina | CHIEF COMMERCIAL OFFICER | 0 | $0 | 2 | $4.24M | $-4.24M |
| Hewes L. Becker | CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $5.28M | $-5.28M |
| Albers Jeffrey W. | director | 0 | $0 | 7 | $8.56M | $-8.56M |
| Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 0 | $0 | 5 | $9.62M | $-9.62M |
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing …
Insider Activity of Blueprint Medicines Corporation
Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $39.68M worth of Blueprint Medicines Corporation stock.
On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $174,552 and sold $22.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.
List of Insider Buy and Sell Transactions, Blueprint Medicines Corporation
| 2025-03-12 | Sale | Albers Jeffrey W. | director | 7,500 0.0114% | $87.80 | $658,500 | -0.87% | |
| 2025-03-06 | Sale | Hewes L. Becker | CHIEF MEDICAL OFFICER | 5,232 0.0081% | $87.69 | $458,804 | +0.15% | |
| 2025-03-05 | Sale | Haviland Kate | CHIEF EXECUTIVE OFFICER | 16,151 0.0249% | $88.80 | $1.43M | -1.53% | |
| 2025-03-05 | Sale | Namouni Fouad | PRESIDENT, R & D | 6,489 0.01% | $88.80 | $576,223 | -1.53% | |
| 2025-03-05 | Sale | Landsittel Michael | CHIEF FINANCIAL OFFICER | 5,284 0.0082% | $88.80 | $469,219 | -1.53% | |
| 2025-03-05 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 6,495 0.01% | $88.80 | $576,756 | -1.53% | |
| 2025-03-05 | Sale | McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 5,262 0.0081% | $88.80 | $467,266 | -1.53% | |
| 2025-03-05 | Sale | Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 3,530 0.0055% | $88.80 | $313,464 | -1.53% | |
| 2025-03-05 | Sale | Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 5,157 0.008% | $88.80 | $457,942 | -1.53% | |
| 2025-03-05 | Sale | Lee Philina | CHIEF COMMERCIAL OFFICER | 3,733 0.0058% | $88.80 | $331,490 | -1.53% | |
| 2025-03-05 | Sale | Hewes L. Becker | CHIEF MEDICAL OFFICER | 4,863 0.0075% | $88.80 | $431,834 | -1.53% | |
| 2025-03-05 | Sale | Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 1,326 0.002% | $88.80 | $117,749 | -1.53% | |
| 2025-03-03 | Sale | Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 3,203 0.0052% | $92.62 | $296,666 | -0.42% | |
| 2025-02-20 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 2,274 0.0036% | $95.14 | $216,348 | -5.82% | |
| 2025-01-21 | Sale | Albers Jeffrey W. | director | 15,161 0.0233% | $109.53 | $1.66M | -14.98% | |
| 2025-01-21 | Sale | Haviland Kate | CHIEF EXECUTIVE OFFICER | 1,446 0.0022% | $110.24 | $159,407 | -14.98% | |
| 2025-01-21 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 2,274 0.0035% | $110.14 | $250,455 | -14.98% | |
| 2025-01-13 | Sale | Albers Jeffrey W. | director | 5,000 0.0078% | $102.28 | $511,400 | -4.04% | |
| 2025-01-13 | Sale | Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 2,250 0.0034% | $100.00 | $225,000 | -4.04% | |
| 2024-12-19 | Sale | Albers Jeffrey W. | director | 15,000 0.0237% | $89.77 | $1.35M | +4.59% |
Total: 326
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.71%
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 168427 0.2636% | $15.09M | 1 | 29 | +11.1% |
| FMR LLC | 264898 0.4145% | $23.73M | 1 | 9 | +9.46% | |
| Goldberg Mark Alan | 10812 0.0169% | $968,538.96 | 1 | 6 | <0.0001% | |
| Demetri George | 5822 0.0091% | $521,534.76 | 1 | 9 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$159,914,414 | 243 | 18.52% | $5.91B | |
$211,610,344 | 91 | 38.45% | $7.69B | |
$52,263,649 | 70 | 1.18% | $4.36B | |
$108,876,545 | 67 | 72.81% | $7.67B | |
$88,307,390 | 38 | -1.70% | $8.38B |
BPMC Institutional Investors: Active Positions
| Increased Positions | 211 | +70.81% | 9M | +13.49% |
| Decreased Positions | 130 | -43.62% | 6M | -9.7% |
| New Positions | 60 | New | 3M | New |
| Sold Out Positions | 31 | Sold Out | 413,878 | Sold Out |
| Total Postitions | 379 | +27.18% | 68M | +3.79% |
BPMC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $663,371.00 | 10.73% | 6.87M | -249,722 | -3.51% | 2024-12-31 |
| Vanguard Group Inc | $654,251.00 | 10.59% | 6.77M | +91,450 | +1.37% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $548,430.00 | 8.87% | 5.68M | +291,822 | +5.42% | 2024-12-31 |
| Wellington Management Group Llp | $413,451.00 | 6.69% | 4.28M | +316,754 | +7.99% | 2024-12-31 |
| State Street Corp | $241,445.00 | 3.91% | 2.5M | -265,495 | -9.6% | 2024-12-31 |
| Fmr Llc | $217,058.00 | 3.51% | 2.25M | -2M | -50.24% | 2024-12-31 |
| William Blair Investment Management, Llc | $187,799.00 | 3.04% | 1.94M | +269,896 | +16.11% | 2024-12-31 |
| Geode Capital Management, Llc | $143,899.00 | 2.33% | 1.49M | +9,914 | +0.67% | 2024-12-31 |
| Macquarie Group Ltd | $121,579.00 | 1.97% | 1.26M | -4,685 | -0.37% | 2024-12-31 |
| Avoro Capital Advisors Llc | $114,435.00 | 1.85% | 1.19M | +1M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.